Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance.

Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX, Fujioka M, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M.

Neuropharmacology. 2007 Mar;52(4):1079-87. Epub 2007 Feb 21.

PMID:
17320118
2.

Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism.

Hayakawa K, Mishima K, Nozako M, Hazekawa M, Irie K, Fujioka M, Orito K, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M.

J Neurochem. 2007 Sep;102(5):1488-96. Epub 2007 Apr 16.

3.

Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism.

Hayakawa K, Mishima K, Abe K, Hasebe N, Takamatsu F, Yasuda H, Ikeda T, Inui K, Egashira N, Iwasaki K, Fujiwara M.

Neuroreport. 2004 Oct 25;15(15):2381-5.

PMID:
15640760
4.

Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism.

Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K, Fujiwara M.

Stroke. 2005 May;36(5):1077-82. Epub 2005 Apr 21.

5.

Delta9-tetrahydrocannabinol (Delta9-THC) prevents cerebral infarction via hypothalamic-independent hypothermia.

Hayakawa K, Mishima K, Nozako M, Hazekawa M, Ogata A, Fujioka M, Harada K, Mishima S, Orito K, Egashira N, Iwasaki K, Fujiwara M.

Life Sci. 2007 Mar 27;80(16):1466-71. Epub 2007 Jan 19.

PMID:
17289082
7.

Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.

González S, Fernández-Ruiz J, Di Marzo V, Hernández M, Arévalo C, Nicanor C, Cascio MG, Ambrosio E, Ramos JA.

Drug Alcohol Depend. 2004 May 10;74(2):159-70.

PMID:
15099659
8.

Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia.

Singh H, Schulze DR, McMahon LR.

Psychopharmacology (Berl). 2011 Jun;215(4):665-75. doi: 10.1007/s00213-010-2162-7. Epub 2011 Jan 19.

9.

Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.

Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, Egawa T, Kitamura Y, Uchida N, Nishimura R, Egashira N, Iwasaki K, Fujiwara M.

Brain Res. 2008 Jan 10;1188:157-64. Epub 2007 Oct 12.

PMID:
18021759
10.

Δ9-Tetrahydrocannabinol attenuates MDMA-induced hyperthermia in rhesus monkeys.

Taffe MA.

Neuroscience. 2012 Jan 10;201:125-33. doi: 10.1016/j.neuroscience.2011.11.040. Epub 2011 Nov 29.

11.

Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors.

Fride E, Ponde D, Breuer A, Hanus L.

Neuropharmacology. 2005 Jun;48(8):1117-29. Epub 2005 Apr 26.

PMID:
15910887
12.

Effects of Delta 9-tetrahydrocannabinol, (R)-methanandamide, SR 141716,and d-amphetamine before and during daily Delta 9-tetrahydrocannabinol dosing.

Lamb RJ, Järbe TU, Makriyannis A, Lin S, Goutopoulos A.

Eur J Pharmacol. 2000 Jun 16;398(2):251-8.

PMID:
10854837
13.

The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.

Moreno-Martet M, Feliú A, Espejo-Porras F, Mecha M, Carrillo-Salinas FJ, Fernández-Ruiz J, Guaza C, de Lago E.

Mult Scler Relat Disord. 2015 Nov;4(6):505-11. doi: 10.1016/j.msard.2015.08.001. Epub 2015 Aug 5.

PMID:
26590655
15.

Protective effects of Delta(9)-tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death.

Chen J, Lee CT, Errico S, Deng X, Cadet JL, Freed WJ.

Brain Res Mol Brain Res. 2005 Apr 4;134(2):215-25.

16.

Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.

Suplita RL 2nd, Eisenstein SA, Neely MH, Moise AM, Hohmann AG.

Neuropharmacology. 2008 Jan;54(1):161-71. Epub 2007 Jul 19.

17.

Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ(9) -tetrahydrocannabinol in Sprague-Dawley rats.

Taffe MA, Creehan KM, Vandewater SA.

Br J Pharmacol. 2015 Apr;172(7):1783-91. doi: 10.1111/bph.13024. Epub 2015 Jan 23.

18.

Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.

Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, Gunasekaran N, Karl T, Long LE, Huang XF, Liu K, Arnold JC, McGregor IS.

Psychopharmacology (Berl). 2011 Nov;218(2):443-57. doi: 10.1007/s00213-011-2342-0. Epub 2011 Jun 11.

PMID:
21667074
19.

Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.

Varvel SA, Bridgen DT, Tao Q, Thomas BF, Martin BR, Lichtman AH.

J Pharmacol Exp Ther. 2005 Jul;314(1):329-37. Epub 2005 Apr 14.

Supplemental Content

Support Center